An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2

Y Yuan Zhang C Caiqian Wang (National Key Laboratory of Agricultural Microbiology) Y Yanhong Zheng (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) F Feiyu Chen (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) Y Yaya Feng (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) L Lingying Fang (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) Z Zongmei Wang (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) M Ming Zhou (Centre for Catalysis and Clean Energy, Gold Coast Campus) Z Zhen F. Fu (National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) L Ling Zhao (National Key Laboratory of Agricultural Microbiology)

Abstract

Integrating complementary vaccine modalities is essential for combating emerging pathogens. Although the recent mRNA-VLP hybrids enable spontaneous virus-like particles (VLPs) self-assembly, thereby enhancing immunogenicity, they fail to elicit robust pulmonary mucosal immunity against respiratory pathogens. Here, we developed Ad5-Envp-VLP, a chimeric adenoviral platform enabling spontaneous in vivo assembly of envelope protein-displaying VLPs using advanced technology that recruits ESCRT (endosomal sorting complex required for transport) via the EABR (ESCRT and ALIX-binding region). Compared with the intramuscular route, intranasal administration of a single-dose Ad5-HA-VLP confers long-lasting protection against both homologous and heterologous influenza A strains. Integrated single-cell RNA sequencing and flow cytometry analyses reveal that intranasal delivery of Ad5-HA-VLP recruits and functionally reprograms lung innate immune cells, promoting antigen presentation and driving robust mucosal secretory IgA (sIgA) secretion and cytotoxic T lymphocyte responses. Similarly, intranasal delivery of Ad5-S-VLP elicits potent cross-neutralizing antibody titers against SARS-CoV-2 variants. Importantly, intranasal immunization with Ad5-S-HA-VLP (coexpressing S- and HA-VLPs) generates dual influenza and SARS-CoV-2 neutralizing antibodies, alongside pulmonary antigen-specific sIgA, confirming Ad5-Envp-VLP as a promising “single-dose multiplexed mucosal vaccine” against respiratory pathogens. Further extended applications show that Ad5-RVDG-VLP also induces broad protective immunity in mouse, dog, and cat models, verifying its feasibility as an efficient rabies vaccine. Collectively, the Ad5-Envp-VLP platform represents a universal and versatile mucosal vaccine strategy, leveraging pulmonary delivery of vectors that encode in vivo-assembling VLPs to concurrently elicit robust mucosal and systemic immunity against a wide spectrum of pathogens.

Article Details

Volume / Issue Vol. 123, Issue 18
Published May 05, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (10)

Y

Yuan Zhang

C

Caiqian Wang

National Key Laboratory of Agricultural Microbiology

Y

Yanhong Zheng

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

F

Feiyu Chen

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

Y

Yaya Feng

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

L

Lingying Fang

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

Z

Zongmei Wang

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

M

Ming Zhou

Centre for Catalysis and Clean Energy, Gold Coast Campus

Z

Zhen F. Fu

National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University

L

Ling Zhao

National Key Laboratory of Agricultural Microbiology